These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21739182)

  • 1. Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma.
    Pachmann K; Camara O; Kroll T; Gajda M; Gellner AK; Wotschadlo J; Runnebaum IB
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1317-27. PubMed ID: 21739182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.
    Camara O; Rengsberger M; Egbe A; Koch A; Gajda M; Hammer U; Jörke C; Rabenstein C; Untch M; Pachmann K
    Ann Oncol; 2007 Sep; 18(9):1484-92. PubMed ID: 17761704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment.
    Camara O; Jörke C; Hammer U; Egbe A; Rabenstein C; Runnebaum IB; Hoeffken K; Pachmann K
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):643-7. PubMed ID: 18936973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.
    Rack B; Jückstock J; Günthner-Biller M; Andergassen U; Neugebauer J; Hepp P; Schoberth A; Mayr D; Zwingers T; Schindlbeck C; Friese K; Janni W
    Arch Gynecol Obstet; 2012 Feb; 285(2):485-92. PubMed ID: 21717141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy.
    Pachmann K; Camara O; Kohlhase A; Rabenstein C; Kroll T; Runnebaum IB; Hoeffken K
    J Cancer Res Clin Oncol; 2011 May; 137(5):821-8. PubMed ID: 20694797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
    Dawood S; Broglio K; Buzdar AU; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2010 Jan; 28(1):92-8. PubMed ID: 19933921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
    Pachmann K; Dengler R; Lobodasch K; Fröhlich F; Kroll T; Rengsberger M; Schubert R; Pachmann U
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):59-65. PubMed ID: 17611779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.
    Georgoulias V; Bozionelou V; Agelaki S; Perraki M; Apostolaki S; Kallergi G; Kalbakis K; Xyrafas A; Mavroudis D
    Ann Oncol; 2012 Jul; 23(7):1744-50. PubMed ID: 22377561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting HER2: recent developments and future directions for breast cancer patients.
    Wang SC; Zhang L; Hortobagyi GN; Hung MC
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.
    Xiao C; Gong Y; Han EY; Gonzalez-Angulo AM; Sneige N
    Ann Oncol; 2011 Jul; 22(7):1547-1553. PubMed ID: 21239403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.
    Park IH; Ro J; Lee KS; Nam BH; Kwon Y; Shin KH
    Ann Oncol; 2009 Jan; 20(1):56-62. PubMed ID: 18664558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
    Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
    Couto Mdo R; Pinto D; Oliveira J; Monteiro A; Pereira D; Medeiros R; Rodrigues H
    Acta Med Port; 2011; 24(1):5-16. PubMed ID: 21672436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
    Diaz NM
    Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphologic features do not influence response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.
    Li X; Kanbour-Shakir A; Dabbs DJ; Bhargava R
    Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):420-5. PubMed ID: 23165332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
    Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG
    J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors.
    Gajda M; Camara O; Oppel S; Kroll T; Jörke C; Krauspe S; Hammer U; Rabenstein C; Untch M; Runnebaum IB; Pachmann K
    Ann Oncol; 2008 Dec; 19(12):2090-1. PubMed ID: 18820243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.